A noninvasive clinicopathologic and gene expression profiling (CP-GEP)–based tool, the Merlin assay, shows promise for identifying recurrence risks in patients with early-stage melanoma who do ...

Biocartis announced the launch of its real-time quantitative polymerase chain reaction assay to detect POLE and POLD1 mutations in endometrial cancer. Biocartis has launched a fully automated, ...